Systematic Review of Phenotypical Characteristics of P51S COCH Mutation
NCT ID: NCT03707756
Last Updated: 2018-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2018-05-01
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is characterized by a late onset of rapid progressive SNHL together with accompanying vestibular impairment. The first reported DFNA9 patients were carrying the c.151 C\>T mutation in COCH, which is the result of a substitution of cytosine by thymine nucleotide of the 151th base pair (c.151C\>T). At protein level, this missense point mutation induces a mistranslation to a serine instead of a proline amino-acid (p.Pro51Ser, (P51S)), producing mutant cochlin that cause a dominant negative effect due to misfolding.
In the perspective of promising future hearing and vestibular treatment developments, such as gene therapy, stem cell therapy, neural regeneration, in association with cochlear and/or vestibular implantation, a more accurate understanding of the onset of the very first signs of the auditory and vestibular deterioration is important. However, in early stages these first signs of impairment are very discrete and pre-symptomatic.
The aim of this systematic review is to identify studies related to DFNA9, caused by the P51S COCH variant, describing detailed genotype-phenotype correlation in relation to the age and to investigate the age of onset of the SNHL and peripheral vestibular function as well as their progression in relation to age.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genotype-phenotype Correlation Study of Presymptomatic and Symptomatic DFNA9 Patients
NCT03716908
Prevalence of POU4F3 and SLC17A8 Mutations
NCT01802190
Genetic Analysis of Human Hereditary Hearing Impairment
NCT00001606
Genetic Feature of Congenital Hearing Loss in Chinese Population
NCT06365749
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan
NCT00341874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Audiometric data were collected using individual measurements or pure tone average incides in the selected records.In case of different audiometric data presentation, for instance audiograms or different pure tone average (PTA) plots against age, a comprehensive assessment and inventory of all individual measurements was conducted. All available measurements at both ears per frequency were inventoried and a binaural mean value for each frequency per age was averaged, before the calculation of the indices. If longitudinal measurements of the same individual were shown, all the available data was included in the assessment.
The following parameters for the audiometric data were inventoried: pure tone average (PTA), Annual Threshold detarioration (ATD) per frequency and/or PTA, Age-related Typical Audiogram (ARTA) and age of onset of the sensorineural hearing loss (SNHL).
For the vestibular function, all different parameters of the vestibular function were inventoried. Normative values, if mentioned, were used to evaluate the measurements. An overall inventory of all individual vestibular measurements in relation to age was conducted.
The following parameters for the vestibular function were inventoried: Time Constant (T) derived from velocity-step test (VST) in seconds, Caloric response gain on electronystagmography, Annual vestibular deterioration rate and age of onset of vestibular dysfunction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sebastien Janssens de Varebeke
principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JessaH-ORL-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.